Colon Cancer Treatment: NICHE-2 Validates Immunotherapy
Maria Babak shared a post by The Babak Lab on LinkedIn:
“ This research highlights a critical step forward in colon cancer treatment using immunotherapy before surgery.
If you’re curious about the evolving strategies in cancer care or how immune-checkpoint inhibitors might redefine treatment for high-risk patients, this is a must-read!
What are your thoughts on using immunotherapy in early-stage cancer treatment?
Do you think neoadjuvant therapies could become the new standard for other types of cancer? Let’s discuss!”
Quoting The Babak Lab’s post:
“ Colon Cancer Treatment: NICHE-2 Validates Immunotherapy
The NICHE-2 trial validated the effectiveness of neoadjuvant immune-checkpoint inhibitors (ICIs) in treating locally advanced, DNA mismatch repair-deficient (dMMR) colon cancer.
It confirmed that using a combination of nivolumab and ipilimumab before surgery significantly improves patient outcomes.
With promising 3-year disease-free survival rates, this study paves the way for a shift in early-stage treatment approaches!
Key highlights:
- Neoadjuvant ICIs (nivolumab and ipilimumab)
- 115 patients, high-risk cases
- Proven safety and efficacy
This could be a game-changer for high-risk colon cancer patients!
Read full article.”
Source: Maria Babak/LinkedIn and The Babak Lab/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023